What is more, Saha et al. reported that administration of PD-L1 antibody (rat clone 10F.9G2) alone showed better therapeutic effects than PD-1 antibody alone, and it significantly increased mean survival time (42 days, n = 7; 25% increase) as compared to its mock (33.5 days, n = 6) in a glioma stem cell-derived glioma model (Saha et al., 2017). Here, PDCD1 is linked to glioma.